SCALE-UP AND TECHNICAL TRANSFER FOR LYOPHILIZED PRODUCTS

Publisher: Baxter BioPharma Solutions

Access this content

Your content has been opened.

Please verify you are a human before downloading this content.

SCALE-UP AND TECHNICAL TRANSFER FOR LYOPHILIZED PRODUCTS has been emailed to . Entered the wrong email?

Don't see the content in your inbox?
Make sure to check your spam and other messages folders.

Can't get to your email right now?

To complete your registration and access this content, enter the sign-in code sent to your email.

Please enter a valid verification code.

Code sent to:

Also, remember to check in your spam, promotions, and other folders.

Register to access this content

By accessing content on the Pharmaceutical Manufacturing Resource Directory you agree to our Terms of Service and Privacy Policy; and, you acknowledge that your information may be shared with the content publisher.

SCALE-UP AND TECHNICAL TRANSFER FOR LYOPHILIZED PRODUCTS

Formulation and process development for injectable products are typically conducted at laboratory-scale. There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation is intended for lyophilization. The process is transferred to full-scale freeze dryers that can be 10 times the size of the laboratory-scale equipment. This whitepaper from Baxter BioPharma Solutions addresses these challenges by: • Examining the different designs for lyophilizers • Discussing the in-process data collected during freeze-drying • Presenting a method of determining equipment capability and comparing data between lab-scale and full-scale equipment Considering the differences in equipment design and capability will aid in the scale-up and technical transfer of new processes from laboratory-scale to full-scale and in transfers between manufacturing sites.

Similar content you might be interested in

Drum Isolator

Publisher: Custom Powder Systems, the Containment Company

Drum Isolator

Safely discharge hazardous or potent material from storage drums.

Download Content »

Aseptic Filling Expertise

Publisher: Dec Group

Aseptic Filling Expertise

Technological developments in the pharmaceutical industry have advanced rapidly over the last decades. One field of particular interest has been aseptic and sterile primary packaging. Primary packaging of pharmaceutical products often involves filling containers (including vials, syringes and bottles) with powders and/ or liquid solutions. Manufacturing staff, equipment and premises are all subject to stringent quality controls – and for good reason: patient safety. In order to ensure the safety and quality of pharmaceutical products, every manufacturer in the pharmaceutical industry is compelled to adhere to the Good Manufacturing Practice (GMP) guidelines. Recently, a complete draft revisionI of Annex 1 (Manufacture of Sterile Medicinal Products) of the GMP has been released. This document intends to provide information on the latest status, trends and technologies in parenteral filling equipment.

Download Content »

Uploaded From lab-bench to large-scale production

Publisher: Frewitt

Uploaded From lab-bench to large-scale production

In formulation development, the scale-up from a lab-bench production of small batches to a large-scale production due to a demand for bigger batches, e.g. for clinical trials or economic reasons, can often be challenging. Thus, the possibility to scale-up the manufacturing process is imperative for the success of a new formulation and should be evaluated during early stages of development. This applies to the production of nanocrystals (NC), which can be used to enhance the skin penetration properties of promising actives in the field of skin therapy, such as the flavonoid curcumin [1-3]. Curcumin is isolated from the rhizome of turmeric and acts as a selective inhibitor of the enzyme phosphorylase kinase. This leads to a positive effect on dermal wound healing after topic application with less inflammation and reduced scarring [2]. However, it shows an insufficient skin penetration, due to its poor aqueous solubility and low bioavailability [1]. Thus, the development of a suitable formulation for curcumin is crucial for its later use in therapy. After formulation development, low energy nanomilling with the NanoWitt-LAB 100 milling equipment enables an easy scale-up of the NC production in continuous operation. Therefore, it can be used as a suitable manufacturing process to determine the feasibility of a largescale production.

Download Content »